To provide long-term capital growth.
Name | % Net Assets |
---|---|
Concurrent Technologies | 4.7% |
AstraZeneca | 4.5% |
Wilmington | 4.3% |
Glaxosmithkline | 4.0% |
Spirax Sarco Engineering | 3.9% |
RWS Holdings | 3.9% |
Cobham | 3.7% |
Next Fifteen Communications | 3.6% |
Brooks MacDonald | 3.2% |
Renishaw | 3.2% |
Key | % Net Assets |
---|---|
Concurrent Technologies | 4.7% |
AstraZeneca | 4.5% |
Wilmington | 4.3% |
Glaxosmithkline | 4.0% |
Other | 82.5% |
Date | 28-Mar-2024 |
---|---|
Bid | 480.08p |
Offer | 483.54p |
Currency | GBP |
Change | 1.97p |
% | 0.41% |
YTD change | 6.01p |
YTD % | 1.26% |
Fund Inception | 11/11/2005 |
---|---|
Fund Manager | Anthony Cross / Julian Fosh |
TER | 1.88 (30-Nov-2013) |
Minimum Investment | |
---|---|
Initial | £2500 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.28 |
You are here: research